Ph3 ready hormone therapy company with an injectable, long-acting GnRH antagonist for prostate cancer and benign prostatic hyperplasia. An injectable enables extended drug activity, which is important for indications with active oral antagonists in late-stage development and also approved agent(s). The safety profile looks good with over 415 subjects dosed over 805 times.
Basic Materials /
22 South Molton Street
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.